BioNTech Results Presentation Deck
Q4 2021 And FY 2021 Financial Results - Profit or Loss
29
(in millions, except per share data)¹
Research & development revenues
Commercial revenues²
Total revenues
Cost of sales
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income less expenses
Operating income / (loss)
Finance income less expenses
Income taxes
Profit / (loss) for the period
Earnings per share
Basic profit / (loss) for the period per share
Diluted profit/ (loss) for the period per share
4Q 2021
€6.6
5,525.9
€5,532.5
(583.2)
(271.5)
(17.9)
(130.9)
170.7
€4,699.7
14.2
(1,547.7)
€3,166.2
€12.96
€12.18
1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context.
Presentation of the consolidated statements of profit or loss has been condensed.
4Q 2020
€65.4
280.0
€345.4
(41.0)
(257.0)
(6.7)
(35.9)
239.4
€244.2
(38.6)
161.3
€366.9
€1.51
€1.43
2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31,
2021. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.
FY 2021
€102.7
18,874.0
€18,976.7
(2,911.5)
(949.2)
(50.4)
(285.8)
504.0
€15,283.8
(237.4)
(4,753.9)
€10,292.5
€42.18
€39.63
FY 2020
€178.8
303.5
€482.3
(59.3)
(645.0)
(14.5)
(94.0)
248.1
€ (82.4)
(63.4)
161.0
€15.2
€0.06
€0.06
BIONTECHView entire presentation